Founded in Shanghai in January 2022, ChainGen Bio covers four core research and development functional areas, including nucleic acid chemistry, biological coupling, drug analysis, and cell biology.
Recently, the biotechnology enterprise ChainGen Bio (Chinese: 迦进生物) successfully racked up in an angel round. The funds would be used for research and development, patent layout, company operation, laboratory platform construction, etc.
Founded in Shanghai in January 2022, ChainGen Bio covers four core research and development functional areas, including nucleic acid chemistry, biological coupling, drug analysis, and cell biology. In addition to R&D, the team also includes project management, BD, and other talents. And it is also one of the first domestic biotechnology companies engaged in public research and development of X-oligo conjugate (XOC). It focuses on the extrahepatic delivery of small nucleic acids by coupling, filling the gap in this subdivided field in China.
ChainGen Bio has made progress in small nucleic acid molecular design and screening after 10 months of research and development.
First of all, in vitro experiments showed that the biological activity of the siRNA ChainGen chosen was about five times higher than that of the most advanced molecule of the competitor. Second, the company has completed animal immunization and screening and is expected to enter the humanization stage in December. Third, at the coupling process level, ChainGen Bio selects the fixed-point method, which means fewer purification steps and more uniform control of molecules.
Dr. Wu Hao, the founder of ChainGen Bio, said that small nucleic acid coupling drugs combine the advantages of target specificity of small nucleic acids and tissue specificity of macromolecular drugs such as antibodies while avoiding traditional antibody-drug conjugates (ADC). Drugs have broad development space due to the risk of accidental release of toxins.